Claims
- 1. An isolated mammalian placenta which has been exsanguinated and perfused under sterile conditions.
- 2. The isolated mammalian placenta of claim 1 wherein the solution used to perfuse the placenta contains an anticoagulant solution.
- 3. The isolated mammalian placenta of claim 1 wherein the solution used to perfuse the placenta contains an antimicrobial solution.
- 4. The isolated mammalian placenta of claim 1 wherein the solution used to perfuse the placenta contains growth factors.
- 5. The isolated mammalian placenta of claim 1 wherein the placenta is human.
- 6. The isolated mammalian placenta of claim 1 which has been stored from about 2 to 24 hours after the expulsion of the placenta from the uterus.
- 7. An isolated mammalian placenta which has been exsanguinated and perfused and incubated under conditions to allow for the production of embryonic-like stem cells and other multipotent stem cells from said placenta.
- 8. The isolated mammalian placenta of claim 7 which has been incubated for a period of about 2 to 24 hours.
- 9. The isolated mammalian placenta of claim 7 which has been perfused or incubated for a period of about 24 to more than 48 hours.
- 10. An isolated, perfused mammalian placenta which comprises viable embryonic-like stem cells.
- 11. The isolated placenta of claim 10 wherein the stem cells are OCT-4− and ABC-p+.
- 12. The isolated mammalian placenta of claim 1 which has been perfused for at least two hours.
- 13. The isolated mammalian placenta of claim 12 which has been perfused for at least eleven hours.
- 14. The mammalian placenta of claim 10 wherein the placenta is recovered after birth.
- 15. The isolated mammalian placenta of claim 13 which has been perfused for at least twenty-four hours.
- 16. The isolated mammalian placenta of claim 10 wherein the placenta is perfused with a solution containing growth factors.
- 17. The isolated mammalian placenta of claim 7 which has been perfused with a solution containing growth factors.
- 18. The isolated mammalian placenta of claim 7 which is human.
- 19. A method of culturing a mammalian placenta comprising obtaining a placenta after expulsion from the uterus, exsanguinating the placenta, and perfusing the placenta under sterile conditions.
- 20. The method of claim 19 wherein the placenta is perfused with a solution containing an anticoagulant solution.
- 21. The method of claim 19 wherein the placenta is perfused with a solution containing an antimicrobial agent.
- 22. The method of claim 19 wherein the placenta is human.
- 23. The method of claim 19 wherein the placenta has been stored for about two to twenty-four hours after expulsion from the uterus.
- 24. The method of claim 19 wherein said expulsion is at birth.
- 25. The method of claim 23 wherein the placenta is stored at room temperature.
- 26. The method of claim 23 wherein the placenta is stored under refrigeration or freezer conditions.
- 27. A method for culturing an isolated mammalian placenta which has been exsanguinated and perfused comprising culturing the placenta under conditions to allow for the production of embryonic-like stem cells from said placenta.
- 28. The method of claim 27 wherein culturing the placenta comprises perfusing the placenta.
- 29. The method of claim 27 or 28 wherein the placenta has been incubated for a period of about twenty-four to forty-eight hours.
- 30. The method of claim 27 wherein the placenta has been perfused for at least two hours.
- 31. The method of claim 30 wherein the placenta has been perfused for at least eleven hours.
- 32. The method of claim 31 wherein the placenta has been perfused for at least twenty-four hours.
- 33. The method of claim 32 wherein the placenta has been preferred for more than forty-eight hours.
- 34. The method of claim 28 wherein the placenta has been perfused with a solution containing growth factors.
- 35. The method of claim 27 wherein the placenta is human.
- 36. An isolated human placental stem cell which is OCT-4+ and ABC-p+.
- 37. The stem of claim 35 wherein the cell is a human cell.
- 38. An isolated mammalian placental stem cell having at least the following characteristics: CD10+, CD29+, CD34−, CD44+, CD45−, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3−, SSEA4−, OCT-4+ and ABC-p+.
- 39. The isolated placental stem cell of claim 35 wherein said cell is SSEA3− and SEA4−.
- 40. A human placental stem cell which has been isolated from a post-partum human placenta after said placenta has been exsanguinated and perfused for at least 11 hours.
- 41. A stem cell producing apparatus which comprises:
(a) a post-partum mammalian placenta which has been exsanguinated and perfused; (b) a means for incubating or culturing the placenta; and (c) a means for detecting stem cells.
- 42. The apparatus of claim 39 further comprising a collection device for collecting stem cells.
- 43. The apparatus of claim 39 further comprising a means for monitoring and adjusting the culture conditions.
- 44. The apparatus of claim 41 wherein the monitoring and adjusting is computerized.
- 45. The apparatus of claim 39 further comprising a cell separation device.
- 46. A method of treating disease in a human which comprises administering a human placental stem of claim 35, 37 or 38.
- 47. A method of transplanting stem cells which comprises administering to a patient in need thereof a human placental stem cell of claim 35, 37 or 38.
- 48. A pharmaceutical composition which comprises a human placental stem cell of claim 35, 37 or 38.
- 49. The pharmaceutical composition of claim 46 which further comprises umbilical cord or placental blood.
- 50. A committed cell which has been differentiated from a human placental stem cell of claim 35, 37 or 38.
- 51. An isolated, homogenous population of human placental stem cells which cap differentiate into all cell types.
- 52. A homogenous population of viable human placental stem cells which exhibit at least the following cell surface markers: OCT-4+ and ABC-p+.
- 53. An isolated, homogenous population of human placental stem cells which is multipotent.
- 54. An isolated placenta containing a cell which is neither fetal nor maternal in origin.
- 55. The stem cells of claim 49 or 51 wherein the stem cells originate from a placenta.
- 56. A composition suitable for bone marrow transplantation which comprises a population of hematopoietic stem cells enriched in cells that are CD34+ and CD38−.
- 57. The composition of claim 53 further comprising cord blood having cells that are CD34+ and CD38+.
- 58. A composition suitable for bone marrow transplantation which comprises a population of hematopoietic stem cells enriched in cells that are CD34− and CD38−.
- 59. The composition of claim 54 further comprising cord blood having cells that are CD34+ and CD38+.
Parent Case Info
[0001] This application is a continuation-in-part of pending applications Ser. No. 01/004,942, filed Dec. 5, 2001 which claims priority to U.S. provisional application No. 60/251,900, filed Dec. 6, 2000, each of which is hereby incorporated by reference. The present application also claims priority to U.S. provisional application No. 60/268,560, filed Feb. 14, 2001, which is hereby incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60268560 |
Feb 2001 |
US |
|
60251900 |
Dec 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10076180 |
Feb 2002 |
US |
Child |
10640428 |
Aug 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10004942 |
Dec 2001 |
US |
Child |
10640428 |
Aug 2003 |
US |